Intra-articular Hyaluronic Acid in Mild to Moderate Knee Osteoarthritis (Ostenil)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01239810
Recruitment Status : Completed
First Posted : November 11, 2010
Last Update Posted : December 9, 2010
Information provided by:
Technische Universität München

Brief Summary:


To assess the impact of intraarticular hyaluronic acid (HA) on clinical outcome and on volumetric and T2 relaxation based changes of articular cartilage in mild to moderate osteoarthritis (OA) of the knee joint.


Patients with moderate OA of the knee [Kellgren-Lawrence II] were recruited for a 6-months prospective, randomized clinical trial evaluating the effect of HA on articular cartilage morphology and composition. Clinical examinations and MRI were performed at baseline, and after 6, 12 and 24 weeks. Cartilage volume, thickness and surface area were determined in cartilage plates and subregions were defined using proprietary software. MRI was performed on a 1.5 Tesla scanner; morphological evaluation was performed using 3D T1-w FLASH Waterexcitation (WE) sequences and T2 maps were calculated from a multiecho, spin-echo sequence.

Condition or disease Intervention/treatment
Osteoarthritis Drug: Hyaluronic Acid

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 34 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effect of Intra-articular Hyaluronic Acid on Articular Cartilage Morphology and Composition in Mild to Moderate Knee Osteoarthritis
Study Start Date : June 2005
Actual Primary Completion Date : November 2006
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources

Group/Cohort Intervention/treatment
Control group
Receiving no treatment
Drug: Hyaluronic Acid
Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
Other Name: Ostenil
hyaluronic acid
treatment group receiving intraarticular hyaluronic acid
Drug: Hyaluronic Acid
Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
Other Name: Ostenil

Primary Outcome Measures :
  1. WOMAC [ Time Frame: 24 weeks ]
    Western Ontario and McMaster University Osteoarthritis Index 24 weeks after drug adminstration

Secondary Outcome Measures :
  1. MRI [ Time Frame: 24 weeks ]
    quantitative assessment of cartilage morphology using 3D T1-weighted FLASH Waterexcitation (WE) sequence following drug administration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
referred from visiting orthopaedic surgeons to our academic outpatient clinic

Inclusion Criteria:

  • History of mild to moderate OA
  • OA grade II

Exclusion Criteria:

  • Intraarticular injections in the affected knee
  • Oral application of glucosamine and chondroitin sulphate during the last 6 months prior to the beginning of the study
  • Clinically significant knee joint effusion
  • Neoplasm
  • Diabetes mellitus
  • Osteonecrosis
  • Rheumatoid arthritis or any other inflammatory arthritis diagnosed by American College of Rheumatology criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01239810

Sponsors and Collaborators
Technische Universität München
Principal Investigator: Rüdiger von Eisenhart-Rothe, M.D. Department of Orthopaedics and Traumatology, Technische Universität München

Responsible Party: Dr. med. Dipl. Kfm. Rüdiger von Eisenhart-Rothe, Arbeitsgruppe Kinematik und Biomechanik Orthopädische Universitätsklinik Friedrichsheim Johann Wolfgang Goethe-Universität, Frankfurt Identifier: NCT01239810     History of Changes
Other Study ID Numbers: TBOSTZKM1
First Posted: November 11, 2010    Key Record Dates
Last Update Posted: December 9, 2010
Last Verified: December 2010

Keywords provided by Technische Universität München:
hyaluronic acid
T2 mapping

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents